Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.76 |
| ▸ | MAOA | P21397 | 5/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.76 |
| ▸ | SDHA | P31040 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | CALML3 | P27482 | 1/20 | 0.76 |
| ▸ | F10 | P00742 | 6/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eperezolid SCHEMBL1176950 | 1.00 | MAOB (0.76) | MAOBMAOAPTGS1SDHALMNA | |
| Eperezolid SCHEMBL29421647 | 1.00 | MAOB (0.76) | MAOBMAOAPTGS1SDHALMNA | |
| Eperezolid SCHEMBL5325217 | 0.99 | MAOB (0.75) | MAOBMAOAPTGS1SDHALMNA | |
| Eperezolid SCHEMBL5328753 | 0.96 | F10 (0.71) | MAOBMAOAPTGS1SDHALMNA | |
| Eperezolid SCHEMBL7497950 | 0.96 | MAOB (0.85) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL6160239 | 0.94 | F10 (0.72) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL6160243 | 0.94 | F10 (0.72) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL4163039 | 0.93 | MAOA (0.67) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL10151505 | 0.93 | MAOB (0.76) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL12674054 | 0.92 | MAOB (0.73) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144187-A1 | COMBINATION OF HYDROLASES AND ANTI-MICROORGANISM DRUGS AND USES THEREOF | Centre for Eye and Vision Research Limited (CN) | 2025-05-08 | — | — | US | claimed |
| US-12285489-B2 | Bone targeted antimicrobial oxazolidinone related compounds, formulations thereof, and uses thereof | EBETINO FRANK HALLOCK (US) | 2025-04-29 | — | — | US | claimed |
| WO-2025082408-A1 | COMBINATION OF HYDROLASES AND ANTI-MICROORGANISM DRUGS AND USES THEREOF | Centre for Eye and Vision Research Limited (CN) | 2025-04-24 | — | — | WO | claimed |
| WO-2024238956-A1 | PRODRUG LINKER COMPOSITIONS AND METHODS OF USE | OHIO STATE INNOVATION FOUNDATION (US) | 2024-11-21 | — | — | WO | claimed |
| EP-4210762-A1 | DRUG CONJUGATES AND USES THEREOF | Supertrans Medical Ltd (IL) | 2023-07-19 | — | — | EP | claimed |
| WO-2022054057-A1 | DRUG CONJUGATES AND USES THEREOF | SUPERTRANS MEDICAL LTD (IL) | 2022-03-17 | — | — | WO | claimed |
| WO-2021257723-A9 | COMPOSITION AND METHOD FOR NEW THERAPEUTIC AGENTS INCLUDING GUANIDINIUM-PRESENTING DENDRIMERS AND BRANCHED STRUCTURES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-03-10 | — | — | WO | claimed |
| WO-2021257723-A1 | COMPOSITION AND METHOD FOR NEW THERAPEUTIC AGENTS INCLUDING GUANIDINIUM-PRESENTING DENDRIMERS AND BRANCHED STRUCTURES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-12-23 | — | — | WO | claimed |
| US-20210369849-A1 | BONE TARGETED ANTIMICROBIAL OXAZOLIDINONE RELATED COMPOUNDS, FORMULATIONS THEREOF, AND USES THEREOF | EBETINO FRANK HALLOCK (US) | 2021-12-02 | — | — | US | claimed |
| EP-3903842-A1 | NOVEL TREATMENT APPROACH BY TARGETED DELIVERY OF BIOACTIVE MOLECULES BIO MODULATED CERAMICS | Moroxite AB (SE) | 2021-11-03 | — | — | EP | claimed |
| EP-1147422-A1 | ASSAYS FOR MODULATORS OF \"ELONGATION FACTOR P\" ACTIVITY | Pharmacia & Upjohn Company (US) | 2001-10-24 | — | — | EP | claimed |
| WO-2001070170-A1 | CONTAINER FOR LINEZOLID INTRAVENOUS SOLUTION | PHARMACIA & UPJOHN COMPANY (US) | 2001-09-27 | — | — | WO | claimed |
| WO-2001070225-A2 | OXAZOLIDINONE TABLET FORMULATION | PHARMACIA & UPJOHN COMPANY (US) | 2001-09-27 | — | — | WO | claimed |
| CN-1305374-A | Oxazolidinones to treat eye infections | UPJOHN CO (US) | 2001-07-25 | — | — | CN | claimed |
| CN-1299281-A | Use of oxazolidinone derivatives for the treatment of psoriasis, arthritis and for reducing the toxicity of cancer chemotherapy | UPJOHN CO (US) | 2001-06-13 | — | — | CN | claimed |
| CN-1298302-A | Topical administration of oxazolidinones for transdermal delivery | UPJOHN CO (US) | 2001-06-06 | — | — | CN | claimed |
| EP-1032386-A1 | USE OF OXAZOLIDINONE DERIVATITIVES FOR TREATING PSORIASIS, ARTHRITIS AND REDUCING THE TOXICITY OF CANCER CHEMOTHERAPY | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-06 | — | — | EP | claimed |
| WO-2000045177-A1 | ASSAYS FOR MODULATORS OF ELONGATION FACTOR P ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2000-08-03 | — | — | WO | claimed |
| US-6040306-A | Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy | PHARMACIA & UPJOHN COMPANY | 2000-03-21 | — | — | US | claimed |
| WO-1999025344-A1 | USE OF OXAZOLIDINONE DERIVATIVES FOR TREATING PSORIASIS, ARTHRITIS AND REDUCING THE TOXICITY OF CANCER CHEMOTHERAPY | PHARMACIA & UPJOHN COMPANY (US) | 1999-05-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369849-A1 | BONE TARGETED ANTIMICROBIAL OXAZOLIDINONE RELATED COMPOUNDS, FORMULATIONS THEREOF, AND USES THEREOF | SOST, BPGM, PTMS | MAOB 2694/4885MAOA 3576/4885PTGS1 4101/4885 |
| US-20250144187-A1 | COMBINATION OF HYDROLASES AND ANTI-MICROORGANISM DRUGS AND USES THEREOF | GAA, BCHE, LCT | MAOB 205/4885MAOA 86/4885PTGS1 3376/4885 |
| US-12285489-B2 | Bone targeted antimicrobial oxazolidinone related compounds, formulations thereof, and uses thereof | SOST, BPGM, PTMS | MAOB 2694/4885MAOA 3576/4885PTGS1 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.